or Try an Advanced Search...

    Technical Analysis for ROIV - Roivant Sciences Ltd.

    Grade Last Price % Change Price Change
    B 11.03 1.38% 0.15
    ROIV closed up 1.38 percent on Friday, April 26, 2024, on 42 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical ROIV trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    MACD Bullish Centerline Cross Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    200 DMA Support Bullish 1.38%
    Gapped Down Weakness 1.38%
    50 DMA Resistance Bearish 1.19%
    Fell Below 20 DMA Bearish 1.19%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.19%
    50 DMA Resistance Bearish 0.82%
    Older End-of-Day Signals for ROIV ...

       Recent Intraday Alerts

    Alert Time
    Up 2% 2 days ago
    60 Minute Opening Range Breakout 2 days ago
    60 Minute Opening Range Breakdown 2 days ago
    50 DMA Resistance 2 days ago
    Rose Above 20 DMA 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ROIV Chart by TradingView
    Basic chart:

    Profile

    Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Autoimmune Disease Inflammation Monoclonal Antibodies Psoriasis Ulcerative Colitis Abdominal Pain Atopic Dermatitis Crohn's Disease Treatment Of Psoriasis

    Is ROIV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Roivant Sciences: Cashing In On Vants And Ventures
    Apr 2 Roivant announces $1.5B share buyback, positive Phase 2 data
    Apr 2 Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
    Mar 27 Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck
    Mar 26 Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
    Mar 18 Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
    Feb 14 The Analyst Landscape: 4 Takes On Roivant Sciences
    Feb 14 Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
    Feb 13 Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
    Feb 13 Roivant Sciences GAAP EPS of $6.03 beats by $5.54, revenue of $37.14M beats by $7.32M
    See more ROIV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.24
    52 Week Low 8.06
    Average Volume 7,451,458
    200-Day Moving Average 10.64
    50-Day Moving Average 10.94
    20-Day Moving Average 10.98
    10-Day Moving Average 10.72
    Average True Range 0.37
    RSI (14) 54.13
    ADX 14.44
    +DI 26.21
    -DI 23.09
    Chandelier Exit (Long, 3 ATRs) 10.68
    Chandelier Exit (Short, 3 ATRs) 11.27
    Upper Bollinger Bands 11.80
    Lower Bollinger Band 10.16
    Percent B (%b) 0.53
    BandWidth 14.89
    MACD Line 0.01
    MACD Signal Line 0.00
    MACD Histogram 0.0039
    Fundamentals Value
    Market Cap 8.87 Billion
    Num Shares 804 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -7.50
    Price-to-Sales 84.25
    Price-to-Book 8.96
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.38
    Resistance 3 (R3) 11.37 11.24 11.32
    Resistance 2 (R2) 11.24 11.15 11.25 11.30
    Resistance 1 (R1) 11.14 11.09 11.19 11.15 11.28
    Pivot Point 11.01 11.01 11.03 11.01 11.01
    Support 1 (S1) 10.90 10.92 10.95 10.91 10.78
    Support 2 (S2) 10.77 10.86 10.78 10.76
    Support 3 (S3) 10.67 10.77 10.74
    Support 4 (S4) 10.68